Key result
Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) require specific management strategies for bleeding compared to warfarin in patients with nonvalvular atrial fibrillation.
Why the study?
Do direct oral anticoagulants alter bleeding risk compared to warfarin in patients with nonvalvular atrial fibrillation?
Do direct oral anticoagulants alter bleeding risk compared to warfarin in patients with nonvalvular atrial fibrillation?
This review summarizes the bleeding risks and management strategies associated with direct oral anticoagulants compared to warfarin in patients with nonvalvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Supports DOAC preference for lower intracranial bleeding; reinforces phase 3 trial data for management decisions.
Eikelboom et al. (2016) conducted a review in nonvalvular atrial fibrillation. Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Bleeding risk. Direct oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) require specific management strategies for bleeding compared to warfarin in patients with nonvalvular atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: